Literature DB >> 19709680

Cannabinoid 1 receptor mediation of spinal cord ischemic tolerance induced by limb remote ischemia preconditioning in rats.

Binxiao Su1, Hailong Dong, Rui Ma, Xijing Zhang, Qian Ding, Lize Xiong.   

Abstract

OBJECTIVE: The aim of this study was to examine the influence of endogenous cannabinoids on neuroprotection of the spinal cord afforded by limb remote ischemic preconditioning.
METHODS: In experiment 1 (RIPC group), 3 cycles of limb remote ischemic preconditioning within different episodes (2, 3, or 5 minutes) were induced before spinal cord ischemia in rats (N = 5, n = 8). In experiment 2, animals were pretreated intravenously by the vehicles, cannabinoid 1 (AM251, 1 mg/kg) or cannabinoid 2 (AM630, 1 mg/kg) receptor antagonist 15 minutes before remote ischemic preconditioning, or else they were subjected to a sham operation. Thirty minutes after the pretreatment, spinal cord ischemia was induced (N = 8, n = 8). In experiment 3, the arachidonylethanolamide and 2-arachidonoylglycerol contents in the spinal cord after remote ischemic preconditioning and spinal cord ischemia were detected in rats (N = 2, n = 12). Spinal cord ischemia was induced by 12 minutes of thoracic aorta occlusion in rats. Neurologic function was assessed 24 and 48 hours after reperfusion. Histopathologic examination was performed and the number of normal neurons in anterior spinal cord were counted.
RESULTS: In experiment 1, 3 cycles of limb remote ischemic preconditioning (3 minutes of ischemia/3 minutes of reperfusion) induced ischemic tolerance on the spinal cords of the rats. The RIPC group showed a significant reduction in motor deficit index (P < .01) as well as an increase in the number of normal neurons (P < .01). In experiment 2, the cannabinoid 1 receptor antagonist AM251 pretreatment abolished the protective effects of remote preconditioning. In experiment 3, arachidonylethanolamide content in spinal cord was elevated by remote ischemic preconditioning in rats.
CONCLUSION: These results indicated that endogenous cannabinoids, through acting on cannabinoid 1 receptors, were involved in the neuroprotective phenomenon on spinal cords of limb remote ischemic preconditioning.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19709680     DOI: 10.1016/j.jtcvs.2009.07.014

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  The cannabinoid WIN55,212-2 protects against oxidized LDL-induced inflammatory response in murine macrophages.

Authors:  Ming-xiu Hao; Li-sheng Jiang; Ning-yuan Fang; Jun Pu; Liu-hua Hu; Ling-Hong Shen; Wei Song; Ben He
Journal:  J Lipid Res       Date:  2010-03-20       Impact factor: 5.922

Review 2.  Biological networks in ischemic tolerance - rethinking the approach to clinical conditioning.

Authors:  Josef Anrather; John M Hallenbeck
Journal:  Transl Stroke Res       Date:  2013-02       Impact factor: 6.829

3.  Protective effect of delayed remote limb ischemic postconditioning: role of mitochondrial K(ATP) channels in a rat model of focal cerebral ischemic reperfusion injury.

Authors:  Jing Sun; Li Tong; Qi Luan; Jiao Deng; Yan Li; Zhaoju Li; Hailong Dong; Lize Xiong
Journal:  J Cereb Blood Flow Metab       Date:  2012-01-25       Impact factor: 6.200

Review 4.  Systematic review of the impact of cannabinoids on neurobehavioral outcomes in preclinical models of traumatic and nontraumatic spinal cord injury.

Authors:  Faheem I Bhatti; Oliver D Mowforth; Max B Butler; Aniqah I Bhatti; Sylva Adeeko; Melika Akhbari; Rory Dilworth; Ben Grodzinski; Temidayo Osunronbi; Luke Ottewell; Jye Quan Teh; Sophie Robinson; Gayathri Suresh; Unaiza Waheed; Benn Walker; Isla Kuhn; Lara Smith; Richard D Bartlett; Benjamin M Davies; Mark R N Kotter
Journal:  Spinal Cord       Date:  2021-08-14       Impact factor: 2.772

5.  Effects of Remote Ischemic Conditioning on Hand Engagement in individuals with Spinal cord Injury (RICHES): protocol for a pilot crossover study.

Authors:  Yu-Kuang Wu; Noam Y Harel; Jill M Wecht; Ona E Bloom
Journal:  F1000Res       Date:  2021-06-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.